-
公开(公告)号：US11559587B2
公开(公告)日：2023-01-24
申请号：US16578601
申请日：2019-09-23
申请人： BioNTech SE , TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg—Universität Mainz gGmbH
发明人： Ugur Sahin , Heinrich Haas , Sebastian Kreiter , Mustafa Diken , Daniel Fritz , Martin Meng , Lena Mareen Kranz , Kerstin Reuter
摘要： The present invention is in the field of immunotherapy, in particular tumor immunotherapy. The present invention provides pharmaceutical formulations for delivering RNA to antigen presenting cells such as dendrite cells (DCs) in the spleen after systemic administration. In particular, the formulations described herein enable to induce an immune response after systemic administration of antigen-coding RNA.
-
公开(公告)号：US11504419B2
公开(公告)日：2022-11-22
申请号：US16172063
申请日：2018-10-26
申请人： BioNTech SE , TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH
发明人： Ugur Sahin , Claudia Paret , Kirsten Vormbrock , Christian Bender , Jan Diekmann
摘要： The present invention relates to a patient-specific tumor treatment targeting individual expression patterns of tumor antigens, in particular shared tumor antigens, and individual tumor mutations. In one aspect, the present invention relates to a method for preventing or treating cancer in a patient comprising the steps of: (i) inducing a first immune response against one or more tumor antigens in the patient, and (ii) inducing a second immune response against one or more tumor antigens in the patient wherein the second immune response is specific for cancer specific somatic mutations present in cancer cells of the patient.
-
公开(公告)号：US11248264B2
公开(公告)日：2022-02-15
申请号：US16920286
申请日：2020-07-02
申请人： TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH , BioNTech SE
发明人： Ugur Sahin , Sebastian Kreiter , Mustafa Diken , Jan Diekmann , Michael Koslowski , Cedrik Britten , John Christopher Castle , Martin Löwer , Bernhard Renard , Tana Omokoko , Johannes Hendrikus De Graaf
IPC分类号： A61K39/00 , C12Q1/6869 , G16B20/00 , G16B40/00 , C12Q1/6886 , G16B20/20
摘要： The present invention relates to the provision of vaccines which are specific for a patient's tumor and are potentially useful for immunotherapy of the primary tumor as well as tumor metastases. In one aspect, the present invention relates to a method for providing an individualized cancer vaccine comprising the steps: (a) identifying cancer specific somatic mutations in a tumor specimen of a cancer patient to provide a cancer mutation signature of the patient; and (b) providing a vaccine featuring the cancer mutation signature obtained in step (a). In a further aspect, the present invention relates to vaccines which are obtainable by said method.
-
公开(公告)号：US11492628B2
公开(公告)日：2022-11-08
申请号：US15763709
申请日：2016-10-05
申请人： BioNTech SE , TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH
发明人： Alexandra Orlandini Von Niessen , Stephanie Fesser , Britta Vallazza , Tim Beissert , Andreas Kuhn , Ugur Sahin , Marco Alexander Poleganov
IPC分类号： C12N15/67 , A47B3/00 , A47B13/02 , A47B33/00 , A47B43/00 , A47B77/02 , A47B77/06 , A47B77/08 , A47B77/16 , A47B77/18 , A47B95/00 , A47C4/00 , A47C4/08 , A47C7/00 , A47K3/28 , B60B33/00 , E04H1/12 , F16C11/04 , C12N5/0735 , C12N15/113 , C12N15/90
摘要： The present invention relates to stabilization of RNA, in particular mRNA, and an increase in mRNA translation. The present invention particularly relates to a modification of RNA, in particular in vitro-transcribed RNA, resulting in increased transcript stability and/or translation efficiency. According to the invention, it was demonstrated that certain sequences in the 3′-untranslated region (UTR) of an RNA molecule improve stability and translation efficiency.
-
公开(公告)号：US10717982B2
公开(公告)日：2020-07-21
申请号：US15325280
申请日：2015-07-06
申请人： BioNTech RNA Pharmaceuticals GmbH , TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH
发明人： Florian Eberle , Ugur Sahin , Andreas Kuhn , Britta Vallazza , Mustafa Diken
IPC分类号： C12N15/68 , C12N15/70 , C12N15/67 , A61K39/00 , A61K48/00 , C12N15/85 , C12P19/34 , C12P21/00
摘要： The present invention relates to nucleic acid molecules containing poly (dA:dT) regions which are stabilized in E. coli, methods of propagating such nucleic acid molecules in E. coli, methods of obtaining RNA, peptides or proteins using such nucleic acid molecules and to RNA which is obtained from such nucleic acid molecules and its use. In particular, the poly (dA:dT) regions contain at least one disruption by a sequence not encoding a sequence solely composed of A residues.
-
公开(公告)号：US11156617B2
公开(公告)日：2021-10-26
申请号：US15550286
申请日：2016-02-09
申请人： BioNTech RNA Pharmaceuticals GmbH , TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH
发明人： Ugur Sahin , Martin Löwer , Arbel D. Tadmor , Sebastian Boegel , Barbara Schrörs , Mathias Vormehr , Sebastian Kreiter
摘要： The present invention relates to methods for predicting T cell epitopes useful for vaccination. In particular, the present invention relates to methods for predicting whether modifications in peptides or polypeptides such as tumor-associated neoantigens are immunogenic and, in particular, useful for vaccination, or for predicting which of such modifications are most immunogenic and, in particular, most useful for vaccination. The methods of the invention may be used, in particular, for the provision of vaccines which are specific for a patient's tumor and thus, in the context of personalized cancer vaccines.
-
公开(公告)号：US10053512B2
公开(公告)日：2018-08-21
申请号：US15227565
申请日：2016-08-03
申请人： Ganymed Pharmaceuticals AG , TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH
发明人： Ugur Sahin , Ozlem Tureci , Rita Mitnacht-Kraus , Stefan Woll
IPC分类号： A61K49/00 , C07K16/00 , C07K16/18 , C07K16/28 , C07K16/30 , G01N1/00 , G01N33/574 , A61K51/10
摘要： The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN18.2 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN18.2.
-
公开(公告)号：US10669322B2
公开(公告)日：2020-06-02
申请号：US15780599
申请日：2016-12-16
申请人： BIONTECH RNA PHARMACEUTICALS GMBH , TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GGMBH
IPC分类号： C07K14/54 , C07K14/705 , C12N15/62 , C07K14/525 , A61K38/00
摘要： The present invention relates to cytokine fusion proteins and to nucleic acid molecules encoding such cytokine fusion proteins. The present invention further relates to cells, non-human organisms, pharmaceutical compositions and kits comprising the cytokine fusion proteins or the nucleic acid molecules encoding them, as well as to their use as medicaments.
-
公开(公告)号：US10301368B2
公开(公告)日：2019-05-28
申请号：US15543566
申请日：2016-01-15
申请人： BioNTech RNA Pharmaceuticals GmbH , Universität Stuttgart , TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz GGmbH
发明人： Ugur Sahin , Friederike Gieseke , Ronald Backer , Sebastian Kreiter , Roland Kontermann , Klaus Pfizenmaier , Sina Fellermaier , Dafne Müller
IPC分类号： C07K14/52 , C07K14/525 , A61K38/17
摘要： The present invention relates to cytokine fusion proteins and to nucleic acid molecules encoding such cytokine fusion proteins. The present invention further relates to cells, non-human organisms. pharmaceutical compositions and kits comprising the cytokine fusion proteins or the nucleic acid molecules encoding them, as well as to their use as medicaments.
-
公开(公告)号：US20240339174A1
公开(公告)日：2024-10-10
申请号：US18289425
申请日：2022-05-04
申请人： BioNTech SE , InstaDeep Ltd.
发明人： Alexander Muik , Asaf Poran , Yunpeng Liu , Ugur Sahin , Karim Beguir , Marcin Skwark , Thomas Pierrot , Yunguan Fu
IPC分类号： G16B20/20 , C07K14/005 , G16B15/30 , G16B40/20
CPC分类号： G16B20/20 , C07K14/005 , G16B15/30 , G16B40/20 , C12N2770/20022
摘要： The present disclosure provides technologies for identifying, characterizing, and/or monitoring sequences of a variant of a reference infectious agent (e.g., but not limited to viral variants, for example in some embodiments SARS-CoV-2 variants) for transmissibility factors and/or immune escape potential, and/or for detecting and/or monitoring variants in environmental or biological samples, and/or for designing, preparing, and/or administering vaccines for such variants.
-
-
-
-
-
-
-
-
-
搜索结果
71 条记录 (耗时 0.027 秒)
